Table 3. Summary of VSLI-associated AEs.
| Toxicity (CTC) | No with grade 1–4 toxicity VSLI dose level (mg·m−2) | ||||
|---|---|---|---|---|---|
| Single-dose group | Multiple-dose group | ||||
| 1.5 (n=5) | 2.0 (n=6) | 2.3 (n=5) | 1.5 (n=6) | 1.8 (n=6) | |
| Neurology | |||||
| Peripheral neuropathy | 2 | 5 | 3 | 5 | 6 |
| Neuropathic pain | – | 2 | 5 | 4 | 6 |
| Gastrointestinal | |||||
| Constipation | 2 | 3 | 3 | 1 | 4 |
| Nausea | 2 | 2 | 2 | 1 | 2 |
| Emesis | 2 | 1 | 2 | 1 | 1 |
| Diarrhea | 1 | – | – | 1 | 1 |
| Abdominal pain | 1 | – | 1 | 1 | 3 |
| Abdominal distention | 1 | 1 | 1 | 3 | 4 |
| Anorexia | – | – | – | 4 | 5 |
| Oral cavity mucositis | – | – | – | 1 | – |
| Blood | |||||
| Leukocytes | 2 | 2 | 1 | 1 | 3 |
| Anemia | – | 1 | 2 | 2 | 3 |
| Lymphopenia | 1 | – | – | – | 1 |
| Neutrophils | – | 1 | – | 2 | 3 |
| Constitutional | |||||
| Fever | – | – | 2 | 3 | 3 |
| Fatigue | – | 1 | – | 1 | 3 |
| Insomnia | – | – | 1 | – | 1 |
| Weight Loss | – | – | – | – | 1 |
| Skin | |||||
| Alopecia | – | – | 2 | – | – |
| Cardiovascular | |||||
| Supraventricular arrhythmia | – | 1 | – | 1 | – |
| Metabolic | |||||
| Hypokalemia | – | – | – | 1 | – |
| Hypomagnesemia | 1 | 1 | – | – | – |
| Hypermagnesemia | – | 1 | – | – | – |
| Hyponatremia | – | – | – | 2 | – |
| Hypocalcemia | – | – | 2 | 4 | 2 |
| Hypercholesteremia | – | – | – | – | 1 |
| Hypertriglyceridemia | – | – | – | 1 | 2 |
| ALT | – | – | – | 3 | 2 |
| AST | – | 1 | – | 1 | 2 |
| Bilirubin | – | – | – | 1 | – |
| Alkaline phosphatase | – | – | – | 1 | – |